3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
Apple's growth these days is a bit modest, as revenue for the last three months of 2024 was up just 4%, but it still has ...
Leerink Partnrs Has Pessimistic View of REGN Q1 Earnings
Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.